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Abstract
Dysregulated extracellular matrix (ECM) metabolism may
contribute to vascular remodeling during the development
and complication of human atherosclerotic lesions. We in-
vestigated the expression of matrix metalloproteinases
(MMPs), a family of enzymes that degrade ECM compo-
nents in human atherosclerotic plaques (n=30) and in unin-
volved arterial specimens (n=11). We studied members of
all three MMP classes (interstitial coilagenase, MMP-1; gel-
atinases, MMP-2 and MMP-9; and stromelysin, MMP-3)
and their endogenous inhibitors (TIMPs 1 and 2) by immu-
nocytochemistry, zymography, and immunoprecipitation.
Normal arteries stained uniformly for 72-kD gelatinase and
TIMPs. In contrast, plaques' shoulders and regions offoam
cell accumulation displayed locally increased expression of
92-kD gelatinase, stromelysin, and interstitial collagenase.
However, the mere presence of MMP does not establish
their catalytic capacity, as the zymogens lack activity, and
TIMPs may block activated MMPs. All plaque extracts con-
tained activated forms of gelatinases determined zymo-
graphically and by degradation of 3H-collagen type IV. To
testdirectly whether atheromata actually contain active ma-
trix-degrading enzymes in situ, we devised a method which
allows the detection and microscopic localization of MMP
enzymatic activity directly in tissue sections. In situ zymog-
raphy revealed gelatinolytic and caseinolytic activity in fro-
zen sections ofatherosclerotic but not ofuninvolved arterial
tissues. The MMP inhibitors, EDTA and 1,10-phenanthro-
line, as well asrecombinant TIMP-1, reduced these activities
which colocalized with regions ofincreased immunoreactive
MMPexpression, i.e.,theshoulders, core,and microvascula-
ture ofthe plaques. Focal overexpression ofactivated MMP
maypromote destabilization andcomplication ofatheroscle-
rotic plaques and provide novel targets for therapeutic in-
tervention. (J. Clin. Invest. 1994.94:2493-2503.) Key words:
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Introduction
Remodeling of the arterial extracellular matrix (ECM)' occurs
during all phases ofhuman atherosclerosis, including acute dis-
ruptions of the plaque that commonly cause acute myocardial
infarction. Lesion development involves migration of leuko-
cytes and smooth muscle cells (SMCs), accumulation of ECM
components, and creation of new capillary beds. Compensatory
enlargement of arteries during plaque evolution involves major
changes in vessel wall architecture (1, 2). At later stages, as
growth ofthe atherosclerotic plaque outstrips this compensatory
ectasia, the lesion causes arterial stenosis, and rupture and
thrombosis may occur. Each of these important steps in plaque
evolution involves modification ofthe ECM, aprocess regulated
at the levels ofboth synthesis and degradation ofmatrix compo-
nents. We andothers (3-6) havepreviously reportedthathuman
vascularcells canproduce in vitro members ofthe matrix metal-
loproteinase (MMP)family, enzymesthat mayplaycrucialroles
in vascularremodelingduring development, growth, andpathol-
ogy (7). After proteolytic activation of their secreted zymogen
forms (8), MMPs can degrade various ECM components at
physiological pH. Henney et al. (9) detected mRNA encoding
stromelysin in atheroma. We investigated here in normal and
atherosclerotic human arteries theexpression and state ofactiva-
tion of members of all three known MMP families: gelatinases
specialized in the digestion of collagen fragments, basement
membrane-type collagens, or elastin; interstitial collagenase
(MMP-1) which digests fibrillar collagens; and stromelysin
(MMP-3), which degrades proteoglycans, fibronectin, laminin,
elastin, and can activate the zymogen forms ofthe other MMPs
as well (10). We also evaluated the expression in these arterial
specimens of the endogenous inhibitors of MMPs, the tissue
inhibitors of metalloproteinases (TIMPs) 1 and 2.
Methods
Reagents
Cells were identified using monoclonal anti-muscle actin HHF-35 (Enzo
Diagnostics, Syosset, NY); monoclonal anti-human macrophage HAM-
56; monoclonal anti-human leukocyte common antigen (LCA); mono-
1. Abbreviations used in this paper: CL, collagenase; GL, gelatinase;
ECM, extracellular matrix; MMP-1, interstitial collagenase; MMP-2, the
72-kD gelatinase; MMP-3, stromelysin; MMP-9, the 92-kD gelatinase;
MMP, matrix metalloproteinase; o.m., original magnification; pro-
MMP-2, zymogen form of the 72-kD gelatinase; pro-MMP-9, zymogen
form of the 92-kD gelatinase; SL, stromelysin; SMC, smooth muscle
cell; TIMP, tissue inhibitor of MMPs.
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Figure 1. Non-atherosclerotic human coronary arteries contain immunoreactive 72-kD GL and TIMPs. Smooth muscle cells in both intima and
media contain immunoreactive 72-kD GL, TIMP-1, and TIMP-2. Arrows point to the internal elastic lamina. Staining for SL in non-atherosclerotic
arteries is weak or absent. Original magnification (o.m.) X400. These results are typical of five specimens studied.
clonal anti-human Tcell CD3; monoclonal anti-human vonWillebrand
Factor (vWF) (Dako Corporation, Carpenteria, CA). Rabbit polyclonal
antibodies against recombinant human collagenase (MMP-1), stromely-
sin (MMP-3), and TIMP-l were obtained as previously described (11).
Monoclonal anti-72-kD-gelatinase (hybridoma CA 719E3C) was pur-
chased from Molecular Oncology (Gaithersburg, MD). Rabbit poly-
clonal antisera against 72-kD gelatinase (MMP-2) and against TIMP-2
purified from human melanoma cells (12, 13) were generously provided
by Dr. William Stetler-Stevensen (National Institutes of Health,
Bethesda, MD). Anti-92-kD-gelatinase polyclonal antibodies were gen-
erously provided by Dr. Howard Welgus (Washington University, St.
Louis, MO) and monoclonal anti-92-kD-gelatinase antibodies (14) by
Dr. Deborah French (State University of NY at Stony Brook, NY).
Human tissue
Atherosclerotic specimens (n=30) and non-atherosclerotic arteries
(n=11) were obtained at surgery or autopsy. Surgical specimens in-
cluded excess human arterial tissue fromtransplant donors and endarter-
ectomy specimens. These tissues were studied by both histological and
biochemical methods.
Tissue sections. Sections were cut from both tissue embedded in
O.C.T. (Miles, Elkhart, IN) and frozen in 2-methylbutane cooled with
liquid nitrogen, and from tissue fixed in 10% formaldehyde and embed-
ded in paraffin.
Arterial extracts. Tissue was stored at -70°C until extraction. Speci-
mens of atherosclerotic plaques (n=16) or non-atherosclerotic arteries
(n=9) were weighed, minced with scissors, and extracted using
chilled glass homogenizers in ice-cold 10 mM Na phosphate, pH 7.2,
containing 150 mM Na chloride (PBS), and 1 % Triton X-100, 0.1%
SDS, 0.5% Na deoxycholate and 0.2% Na azide (PBSTS).
Immunoprecipitation
Rabbit polyclonal antibodies raised against the 72-kD gelatinase were
first incubated with protein A-Sepharose (Sigma Chemical Co., St.
Louis, MO) at room temperature for 1 h. The excess anti-serum was
washed off and the tissue extracts were added to the primary antibodies
bound to protein A-Sepharose. To immunoprecipitate the 92-kD gela-
tinase, the monoclonal antibody was added to protein A-Sepharose at
the sametime asthetissueextracts. After2 h ofincubation the Sepharose
was washed withPBSTS, the immunoprecipitates were elutedbyheating
at 65°C in nonreducing SDS-PAGE sample buffer and loaded on gelatin-
containing gels.
SDS-PAGE zymography
SDS polyacrylamide gels containing gelatin or casein (1 mg/ml) were
used to identify proteins with gelatinolytic or caseinolytic activity (4)
extracted from the tissue. This method detects both activated and zymo-
gen forms of MMPs. In the presence of SDS otherwise inactive forms
can lyse the substrate contained in the gel due to detergent-induced
conformational change. After electrophoresis, gels were incubated in
2.5% Triton X-100 (2 x 15 min), then overnight at 37°C in 50 mM
Tris-HCl, pH 7.4, containing 10 mM Ca chloride and 0.05% Brij 35
(Sigma Chemical Co.). Identical gels were incubated in the above buffer
containing either 20 mM EDTA, an inhibitor ofMMPs, or 1 mM PMSF,
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Arteries (N, n = 11) and in Atherosclerotic Arteries (A, n = 30): Interstitial CL, 72-kD GL, SL, 92-kD GL, TIMP-J and TIMP-2
Intimal Medial Microvasc
SMCs SMCs Luminal EC EC Macrophages
CL N (n = 5) 0.80±0.40 0.80±0.40 0.00±0.00 N.P. N.P.
(MMP-1) A (n = 15) 1.93±0.25 1.60±0.49 1.33±0.60 1.71±0.45 1.87±0.34
72 kDa GL N (n = 4) 1.50±0.50 1.50±0.50 0.50±0.87 N.P. N.P.
(MMP-2) A (n = 16) 1.94±0.24 1.25±0.43 0.87±0.34 1.00±0.00 1.69±0.46
SL N (n = 5) 0.80±0.40 0.60±0.44 0.20±0.40 N.P. N.P.
(MMP-3) A (n = 14) 2.00±0.00 1.25±0.43 0.75±0.43 1.67±0.37 1.69±0.46
92 kDa GL N (n = 5) 0.80±0.40 0.60±0.80 0.20±0.40 N.P. N.P.
(MMP-9) A (n = 14) 1.86±0.35 1.75±0.43 1.14±0.64 1.20±0.75 1.79±0.41
TIMP-1 N (n = 5) 1.60±0.49 1.60±0.49 0.25±0.43 N.P. N.P.
A (n = 15) 1.87±0.34 2.00±0.0 0.93±0.46 1.00±0.00 1.93±0.25
TIMP-2 N (n = 4) 1.75±0.43 1.75±0.43 2.00±0.00 N.P. N.P.
A (n = 17) 1.76±0.42 2.00±0.00 1.44±0.61 1.73±0.45 1.64±0.48
Staining was evaluated in SMCs, luminal endothelial cells and in microvascular endothelium of the plaques (microvasc EC), and in macrophages.
Consistent positive staining was recorded as (2), variable or weak staining (1), no staining as (0). N.P. = cells not typically present in the specimens.
Results are reported as mean ± standard deviation of the average score. Variation of the score assigned by two independent observers was in the
range of standard deviation. These data are not continuously distributed and are intended to convey the degree ofconsistency ofthe results obtained
by immunocytochemistry in the entire sample, rather than to give a quantitative representation (i.e., in non-atherosclerotic tissue a score of 1.6 for
TIMP-1 vs. 0.8 for stromelysin does not imply twice as much TIMP-1 protein).
an inhibitor of serine proteases. Gels were then fixed and stained with
Colloidal Brilliant Blue G (Sigma Chemical Co.).
Immunocytochemistry
Staining was performed on frozen sections after fixation in cold acetone
(-20°C) or on paraffin sections after deparaffinization with xylene and
ethanol, using the same panel of antibodies and the same immunostain-
ing protocol. The specificity ofthe anti-MMP and anti-TIMP antibodies
used for immunocytochemistry was previously confirmed in our labora-
tory by immunoprecipitation and Western blotting ofrespective antigens
secreted in vitro by cultured human vascular smooth muscle cells (6).
Endogenous peroxidase activity was reduced by preincubation of sec-
tions with 0.3% hydrogen peroxide in Dulbecco's PBS. The sections
were then incubated with primary antibodies, diluted in PBS supple-
mented with 10% horse serum (HyClone, Logan, UT), at room tempera-
ture for 60 min. After washing in PBS and then in 100 mM Tris-HCl,
150 mM Na chloride containing 2% horse serum, species-appropriate
biotinylated secondary antibodies were applied followed by avidin-
peroxidase complexes (Vector Laboratories, Burlingame, CA) and the
reaction was visualized with 3-amino-9-ethyl carbazole as substrate
(AEC; Sigma Chemical Co.). In the case of double immunolabeling,
the specimens were treated for 15 min with an avidin/biotin blocking kit
(Vector Laboratories) after the first staining, then processed for detection
of the second antigen using streptavidin coupled to alkaline phosphatase.
This second reaction was developed using a Fast Blue substrate. Sections
were counterstained with Gill's Hematoxylin (Sigma Diagnostics). Omis-
sion of primary antibodies and staining with type- and class-matched
irrelevant immunoglobulin served as negative controls.
Detection ofenzymatic activity in vitro
Enzymatic activity in tissue extracts. Type IV collagenase activity in
human arterial tissue extracts was investigated using human 3H-collagen
type IV (DuPont-NEN, Boston, MA) as a substrate (10), according to
the protocol suggested by the manufacturer. Radiolabeled collagen (0.7
Hg, specific activity 1.4 pCilsg) was added over tissue extracts of non-
atherosclerotic or atherosclerotic tissue containing 50 tg total protein
in PBSTS buffer. Incubations were performed at 37°C for 24 h in the
presence or absence of 20 mM EDTA, which inhibits MMPs, or of 10
mM p-aminophenyl mercuric acetate (APMA), an activator of MMPs.
The reaction was stopped by boiling in SDS-PAGE sample buffer and
products analyzed by SDS-PAGE. Degradation ofradiolabeled collagen
was detected by fluorography ofdried polyacrylamide gels impregnated
with EN3HANCE (DuPont-NEN).
Detection ofenzymatic activity in tissue sections by in situ
zymography
We adapted for this purpose an approach previously used for macro-
scopic detection of collagenase activity released by tissue slices (15).
Detection of MMP activity in thin tissue sections required substrates
with sensitivity and resolution suitable for microscopy. We identified
suitable substrates for two different types of MMPs.
(a) Detection ofcaseinolytic activity used casein coupled to fluores-
cent molecules. Frozen sections were applied to glass slides covered
with afilm made from 1 mg/ml casein-resorufin (BoehringerMannheim,
Indianapolis, IN) or casein-FITC (Sigma Chemical Co.) mixed (1:1)
with 1I% agarose melted in 50 mM Tris-HCl, pH 7.4, containing 10
mM Cachloride and0.05% Brij 35. Afterincubation oftissue specimens
(vide infra), examination by epifluorescence permitted detection ofareas
of caseinolytic activity as zones lacking fluorescence, and therefore
appearing as black holes in the fluorescent substrate films.
(b) To detect gelatinolytic activity, glass slides holding frozen tissue
sections were dipped into NTB 2 photographic emulsion (Eastman Ko-
dak Co., Rochester, NY), normally used for autoradiography and whose
main component is gelatin. Slides were incubated in both cases into
humidified chambers for various lengths of time. Subsequently, glass
slides covered with emulsion were dried, processed by photographic
development, and examined with a Nikon Optiphot-2 microscope in
transmitted light. The background of these specimens is black due to
exposure ofemulsion to ambient light during processing, while lysis of
gelatin in the emulsion produces transparent spots on the slides.
Regional Overexpression ofMatrix-degrading Enzymes in Human Atheroma 2495-
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Figure 2. Increased regional expression of immunoreactive MMPs in atherosclerotic plaques. Left panels show representative results obtained on
non-atherosclerotic coronary arteries; (upper left) SL (arrows point to the internal elastic lamina, o.m. X40); (center and bottom) details of SL and
CL staining (o.m. X400). Right panels show staining ofan atherosclerotic plaque in a coronary artery. Areas ofincreased immunoreactivity, enclosed
in boxes in the low magnification view of the plaque (upper right) (o.m. X40), are shown at higher power (o.m. X400) in the two panels beneath;
(middle right) the plaque's fibrous cap; (lower right) a portion of one shoulder of the atheroma.
During three independent experiments using in situ zymography, 5-
15 serial sections ofeach lesion were processed using the three different
substrates. Test incubations were performed at ambient temperature.
Controls for detection ofenzymatic activity included incubation of sec-
tions at 4°C or in the presence of chemical inhibitors of MMPs, such
as EDTA and 1,10-phenanthroline (SigmaChemical Co.), orofrecombi-
nant human TIMP-1, a physiological MMP inhibitor.
Non-atherosclerotic arteries contain ubiquitous immunoreac-
tive 72-kD gelatinase (MMP-2) and TIMPs 1 and 2. SMCs
in all layers of non-atherosclerotic arteries contained 72-kD
gelatinase (MMP-2), an MMP specialized in the degradation of
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Figure 3. In human atherosclerotic plaques, foam cells stain with antibodies against all MMPs studied and their inhibitors. Staining ofserial sections
for SL, interstitial CL, 72-kD gelatinase, and TIMP-1 is shown (o.m. Xl,000). These results are typical of 30 plaques studied. The three panels on
the left show staining of an area rich in SMC-derived foam cells, formally identified using anti-actin antibodies (bottom left), while the right-hand
panels show staining offoam cells derived from macrophages, identified with the monoclonal antibody HAM-56 (bottom right). Double immunostain-
ing with anti-MMPs antibodies (reddish-brown reaction) and cell type-specific antibodies (blue reaction product) for identification of SMC or
macrophage (MO) derived foam cells showed colocalization (purple) of MMPs with both cells types (o.m. Xl,000).
type IV collagen. The endogenous inhibitors TIMP-1 and
TIMP-2 showed similar immunolocalization (Fig. 1 and Table
I). Non-atherosclerotic arteries stained weakly or not at all for
the other three MMPs studied, the 92-kD gelatinase (MMP-9),
interstitial collagenase (MMP-1), or stromelysin (MMP-3) (Fig.
2). Luminal endothelium of these arteries usually stained with
anti-72-kD gelatinase and anti-TIMP-2 (Fig. 1 and Table I).
Atheromata contain in addition immunoreactive interstitial
collagenase (MMP-1), 92-kDgelatinase (MMP-9), andstromel-
ysin (MMP-3) in macrophages, smooth muscle cells, lympho-
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Figure 4. Leukocyte infiltrates, identified with an antibody raised against the common leukocyte antigen (LCA) stain for all MMPs studied (o.m.
XlOO). Note the colocalization of MMPs and TIMP-1 with small lymphocytes in this example.
cytes, and endothelium. In contrast to normal arteries, athero-
sclerotic plaques stained for all MMPs tested. Increased MMP
immunoreactivity localized particularly with the fibrous cap,
the shoulders of the lesions, and the base of the lesions' lipid
core (Fig. 2). Staining of serial sections, as well as double
immunostaining, indicated that both macrophages and SMCs
contained immunoreactive MMPs and TIMPs (Fig. 3, Table
I). Areas rich in lymphocytes also colocalized with all MMPs
examined (Fig. 4). Interstitial collagenase, undetectable in the
luminal endothelium of non-atherosclerotic arteries, immunolo-
calized to the luminal endothelium covering plaques, suggesting
a novel marker of activation of endothelial cells overlying ath-
erosclerotic lesions (Fig. 5). The microvascular endothelium of
theplaque neovessels also contained immunoreactive interstitial
collagenase (Fig. 5).
Atherosclerotic plaques contain activated MMPs. The in-
creased MMP immunoreactivity documented in atherosclerotic
lesions (Table I) does not necessarily correspond to augmented
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Figure 5. Endothelial cells in atherosclerotic plaques stain for interstitial collagenase. (Upper two panels) Luminal endothelium covering a carotid
plaque stains for CL, while endothelium of a non-atherosclerotic carotid artery does not (o.m. X400). (Lowerpanels) Plaque microvessels (o.m.
XI00) identified with antibodies against von Willebrand Factor(vWF) contain interstitial CL. Some ofthecapillaries are shown athighermagnification
in the right panels (o.m. X400). These results are typical of 8 non-atherosclerotic arteries and 22 plaques stained for CL.
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Figure 6. Identification of gelatinolytic proteins in extracts of human
arterial tissue by SDS-PAGE zymography. Equal amounts of total pro-
tein were loaded on each lane of a gelatin-containing gel. On this gel,
extracts obtained from four non-atherosclerotic arteries and four athero-
sclerotic plaques were run in parallel with positive controls of culture
media conditioned by fibrosarcoma cells. Unstimulated (-) fibrosar-
coma cells are known to secrete the zymogen form of the 72-kD gela-
tinase (pro-MMP-2), while cells stimulated (+) with phorbol ester acti-
vate MMP-2 and release the pro-92-kD gelatinase (pro-MMP-9). The
results displayed here represent those obtained in multiple experiments.
All atherosclerotic tissue extracts tested (n =16) displayed gelatinolytic
activity comigrating with the zymogen forms of the two gelatinases,
pro-MMP-2 and pro-MMP-9. Non-atherosclerotic extracts (n =9) typi-
cally contained pro-MMP-2 and variable amounts of pro-MMP-9. Only
the plaques contained the activated forms of both MMP-2 and
MMP-9.
enzymatic activity since all MMPs require activation before
they can digest their substrates (16). Moreover, areas that con-
tained MMPs in the plaques also contained TIMPs, molecules
that can prevent the matrix-degrading action and activation of
MMPs (17). Since immunocytochemistry with available anti-
bodies did not distinguish between the zymogen and activated
forms of MMPs, we sought other approaches to determine
whether the arterial tissue contained activated forms of MMPs.
SDS-PAGE zymography, a method that allows identification of
proteins with gelatinolytic activity, demonstrated that all ex-
tracts ofuninvolved tissues (n=9) and all plaque extracts inves-
tigated (n=16) contained the zymogen form of the 72-kD gela-
tinase (pro-MMP-2) (Fig. 6 and datanot shown). By comparison
with this gelatinase, non-atherosclerotic tissue extracts con-
tained much smaller amounts ofthe zymogen form ofthe 92-kD
gelatinase (pro-MMP-9). All endarterectomy extracts contained
pro-MMP-9 and the activated forms ofboth gelatinases, MMP-
2 andMMP-9. In addition to theirpattern ofmigration, immuno-
precipitation formally established the identity of these gela-
tinases (data not shown).
The presence of activated gelatinases in the tissue extracts
was further documented by enzymatic assay using radiolabeled
collagen type IV, a typical substrate for gelatinases (also known
as type IV or type V collagenases). Plaque extracts contained
type IV collagenolytic activity as demonstrated by fluorography
of radiolabeled collagen incubated with the extracts (data not
shown). This enzymatic degradation did not require chemical
activation of the extracts, indicating the presence of endoge-
nously activated gelatinases, and was inhibited by EDTA, con-
sistent with the metal-dependence characteristic of MMPs. Ex-
tracts of non-atherosclerotic tissue assayed in the same manner
did not contain type IV collagenolytic activity (not shown).
Regional overexpression of matrix degrading activities in
situ. To localize MMP activity microscopically within athero-
sclerotic plaques, serial frozen sections of some of the freshly
excised surgical specimens were analyzed by both in situ zy-
mography and immunocytochemistry (Fig. 7). Areas of both
gelatinolytic and caseinolytic activity localized in the same re-
gions in all the plaques examined (n=5). A major area of sub-
strate lysis localized in the shoulders ofplaques, the same areas
of increased expression of immunoreactive MMPs 1,3, and 9.
The core of the plaques also displayed gelatin or casein lysis.
In situ zymographic signals diminished in sections incubated at
4°C (instead of ambient temperature), or in the presence of
EDTA or 1,10-phenanthroline (Fig. 7 and data not shown).
Addition of recombinant human TIMP-1 to the incubation
buffer also reduced the extent of the fluorescent substrates lysis
by atherosclerotic specimens (data not shown). The persistence
of some signal in the presence ofthese inhibitors could indicate
incomplete inhibition of MMPs, or the participation of non-
metalloenzymes (e.g., serine proteases) in substrate lysis. The
non-atherosclerotic arteries (n=3) and the uninvolved areas of
atherosclerotic specimens did not exhibit enzymatic activity de-
termined by this method (Fig. 8).
Discussion
Inboth uninvolved and atherosclerotic arteries SMCs stainedfor
MMP-2, TIMP-1, and TIMP-2. Gelatin zymography of arterial
tissue extracts also showed thepresenceofMMP-2. This finding
agrees well with the constitutive expression of these molecules
in vitro by human vascular SMCs previously reported (5, 6).
However, unlike atherosclerotic tissue, uninvolved arteries did
not appear to contain active MMPs. MMP-2 associates tightly
with its selective endogenous inhibitor TIMP-2, also uniformly
present in normal arteries. Indeed, vascular SMCs (6) and other
cells (13, 18) usually secrete MMP-2 in a complex with its
inhibitor, indicating at least stoichiometric equivalence of the
enzyme and inhibitor. Thus, TIMPs probably limit the matrix-
degrading potential of the consitutively expressed MMP-2 in
normal vessels, consistent with our in situ zymographic results.
In addition to the 72-kD gelatinase (MMP-2), SMCs within
atherosclerotic plaques also contained stromelysin, interstitial
collagenase, and 92-kD gelatinase. In cultured human SMCs
(6), cytokines such as IL-I or TNF-a induce the expression of
the same three MMP we found augmented in plaques in situ.
The same specimens of human atherosclerotic plaques con-
tained regions of immunoreactive IL-I and TNF-a associated
with macrophages or SMCs (data not shown), as previously
described (19-21). In addition to increasing MMP gene expres-
sion, cytokines may regulate activation of MMPs (6) through a
cell-mediated mechanism (22), orregulateplasmin activity (23),
a putative in vivo activator of MMPs.
Macrophages accumulate in rupture-prone regions of
plaques (24), and in our specimens colocalized with all MMPs
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Figure 7. Detection of MMP immunoreactivity and enzymatic activity in frozen sections of human atherosclerotic plaques. Serial sections were
analyzed by immunocytochemistry, (leftpanels) and in situ zymography (rightpanels). Five atherosclerotic plaques were stained for several MMPs
and TIMPs and processed during three independent experiments for detection of gelatinolytic or caseinolytic activity by in situ zymography. Areas
of intense caseinolytic activity, detected as the black spots on the bright background of the fluorescent substrate, typically localized to the shoulders
of the plaques. The lytic activity seemed to diffuse into the portions of the overlay in periluminal areas. Gelatinolytic activity was detected using
a gelatin-containing photographic emulsion. Due to exposure to ambient light and subsequent photographic processing, the background of this
substrate is black, gelatin lysis produces transparent spots. The main areas of immunoreactivity for MMPs in the tissue colocalized with the
degradation of MMP substrates in contact with serial sections, suggesting the presence of activated forms of the enzymes in the shoulders of the
plaques. (Lower right) Incubation of a serial section in the presence of a MMP inhibitor (1,10-phenanthroline) substantially reduced the extent of
casein substrate lysis, indicating that most of the caseinolytic activity was due to MMPs. (Lower left) Control for immunocytochemistry, sections
processed in the absence of primary antibodies (-1° antibodies).
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Figure 8. Normal artery analyzed by immunocytochemistry for stromelysin, its endogenous inhibitor, TIMP-1, and macrophages (MO), and by in
situ zymography (lower rightpanel). Non-atherosclerotic arteries (n=3) did not produce lysis of any of the MMP substrates (n=3), as demonstrated
in this case by the homogeneously bright fluorescent layer of casein-resorufin.
we studied. Henney et al. (9) detected by in situ hybridization
stromelysin mRNA in some ofthehuman atherosclerotic lesions
that they investigated, mostly in macrophages and in a few
cases in scattered SMCs. By immunocytochemistry, we found
even more widespread stromelysin expression, as all plaques
contained numerous immunoreactive macrophages and SMCs
within the cap and shoulders. This difference may result from
a higher expression of stromelysin protein than its mRNA, the
relative stability or concentrations of the protein and RNA, or
the sensitivity of the methods used for their detection. In addi-
tion to stromelysin, we found that macrophages also stained
for interstitial collagenase and the two gelatinases. Therefore,
macrophages, infrequent in normal arterial tissue, seem indeed
to provide an additional source of matrix-degrading enzymes
in the atherosclerotic plaques. Lymphocytes, another important
component of the leukocytic infiltrate of plaques (25) also ex-
pressed MMPs.
Both the endothelium overlying plaques and that of the
lesion's microvasculature expressed interstitial collagenase, an
enzyme not detected in normal endothelium. Cultured endothe-
lial cells can express collagenase after stimulation by phorbol
ester orcertain cytokines (4). Expression ofinterstitial collagen-
ase by the endothelium ofmicrovessels forming in plaques may
aid migration of endothelial cells through the vessel's matrix
during angiogenesis, acharacteristic ofhuman plaque evolution.
ECM constitutes the bulk of many advanced atherosclerotic
plaques. Therefore, ECM metabolism in atherosclerosis must
favor overall net accumulation rather than degradation ofmatrix
components. However, focal accumulation of cells that overex-
press activated forms of MMPs may promote local destruction
ofECM. Ourimmunohistochemical data demonstrated this deg-
radative potential in plaque regions particularly vulnerable to
rupture (26, 27).
However, TIMPs can interfere with the proteolytic pro-
cessing ofMMP zymogens, as well as block substrate binding to
activated MMPs. MMPs can therefore perform their biological
function only after activation, and where and when a local stoi-
chiometric excess over endogenous inhibitors prevails (28). Im-
munocytochemistry cannot distinguish quantitatively such im-
balances between MMPs and TIMPs. To explore whether
MMPs expressed in key locations in the plaques may actually
exert their enzymatic activity, we developed a method for the
microscopic localization of MMP enzymatic activity directly in
sections ofarterial tissue. This approach revealed MMP activity
in the plaques and allowed the microscopic localization ofthese
sites. Zones of gelatin or casein lysis colocalized respectively
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tions obtained from the same lesion. These findings indicate
that increased extracellular matrix degradation may occur in
regions of increased MMP expression in atheroma, such as the
plaque's shoulders and core. Moreover, such regions colocalize
with those independently shown to be sites of maximal circum-
ferential stress (27) and prone to clinical rupture (26). Our re-
sults thus suggest a biochemical mechanism for destabilization
of human atheroma that commonly causes acute clinical mani-
festation, including many strokes and myocardial infarctions.
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